company background image
ECX logo

Epigenomics DB:ECX Stock Report

Last Price

€1.15

Market Cap

€1.0m

7D

43.8%

1Y

-32.2%

Updated

16 Feb, 2025

Data

Company Financials

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

My Notes

Capture your thoughts, links and company narrative

Epigenomics AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Epigenomics
Historical stock prices
Current Share Price€1.15
52 Week High€2.30
52 Week Low€0.50
Beta1.03
1 Month Change-8.00%
3 Month Change8.49%
1 Year Change-32.15%
3 Year Change-89.07%
5 Year Change-99.56%
Change since IPO-99.81%

Recent News & Updates

Recent updates

Shareholder Returns

ECXDE BiotechsDE Market
7D43.8%-3.2%2.7%
1Y-32.2%-7.9%17.0%

Return vs Industry: ECX underperformed the German Biotechs industry which returned -7.9% over the past year.

Return vs Market: ECX underperformed the German Market which returned 17% over the past year.

Price Volatility

Is ECX's price volatile compared to industry and market?
ECX volatility
ECX Average Weekly Movement27.8%
Biotechs Industry Average Movement5.5%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.1%
10% least volatile stocks in DE Market2.5%

Stable Share Price: ECX's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: ECX's weekly volatility has increased from 21% to 28% over the past year.

About the Company

FoundedEmployeesCEOWebsite
19986Noel Dohenywww.epigenomics.com

Epigenomics AG does not have significant operations. Previously, it was involved in liquid biopsy for the early detection of cancer. The company was founded in 1998 and is based in Heidelberg, Germany.

Epigenomics AG Fundamentals Summary

How do Epigenomics's earnings and revenue compare to its market cap?
ECX fundamental statistics
Market cap€1.01m
Earnings (TTM)€2.96m
Revenue (TTM)€136.23k

0.3x

P/E Ratio

7.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ECX income statement (TTM)
Revenue€136.23k
Cost of Revenue€13.91k
Gross Profit€122.32k
Other Expenses-€2.84m
Earnings€2.96m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)3.39
Gross Margin89.79%
Net Profit Margin2,176.13%
Debt/Equity Ratio-136.9%

How did ECX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/16 10:20
End of Day Share Price 2025/02/14 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Epigenomics AG is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hans Bjorn BostromEdison Investment Research
Marietta Miemietzequinet Bank AG (ESN)
Simon ScholesFirst Berlin Equity Research GmbH